Articles tagged with Prostate Cancer
A new study presents contrast-enhanced subharmonic imaging (SHI) as a promising tool for detecting prostate cancers not identified by MRI. SHI provides improved contrast signal and tissue suppression, leading to better visualization of microvascular architecture.
A new study from Ohio State University suggests that a comprehensive exercise and diet program in a group setting can help prostate cancer patients avoid weight gain and strength loss, reducing the risk of chronic health problems. The study found significant differences between men who participated in the program and those who did not.
Researchers have developed a new technology that can characterize gene expression at the level of individual cells in prostate cancer. The technique uses magnetic nanoparticles to trap and analyze circulating tumor cells, allowing for rapid and accurate detection of biomarkers associated with drug resistance.
A study published in the Journal of Clinical Oncology found that taking a standard prostate cancer drug with food can boost its impact and lower costs. By decreasing the daily dose, preventing digestive issues, and cutting costs by 75 percent, patients could save up to $300,000 per month.
A new approach to analyzing prostate gland tissue uses cellular metabolites to differentiate between aggressive and less aggressive tumors. The study found that metabolite levels can predict tumor grade, stage, and recurrence risk, helping guide treatment strategy.
Researchers discover microRNA molecule miR-940 that alters bone structure in late-stage prostate cancer. The molecule promotes osteoblastic lesions, which can cause severe pain and structural weakness.
A new analysis has found that the PIVOT study's patient population was not representative of real-world patients, with those in the trial being older and sicker. This raises significant questions about the validity of the study's findings and potential treatment recommendations.
A new machine learning model can accurately predict which patients are most likely to benefit from prostate multiparametric MRI (mpMRI), allowing for optimized patient selection and resource allocation. The model showed high accuracy in predicting PI-RADS category 4 or 5 lesions, with a sensitivity of 75% and specificity of 82%.
A study by Tampere University found new prostate cancer mechanisms that are not shown by genomic alterations, including changes in the citric acid cycle. Several potential new biomarkers of prostate cancer were also discovered.
A new study using Medicare claims data found that finasteride significantly reduces prostate cancer risk over a period of 16 years, with a 21% decrease in risk compared to those on a placebo. This long-term benefit is twice as long as previously recorded.
The study found that nearly half of the wives reported that their partner's health problem affected their own health, with many feeling increasingly socially isolated. The women also expressed concerns about the role change in their relationship as their husbands became less able to fulfill their usual roles.
A new study reveals that prostate MRI scans can reduce the number of invasive biopsies by up to 28% and detect more harmful cancers. The results show that using MRI to target biopsies leads to more significant cancer diagnoses, while also reducing unnecessary diagnoses.
A Chinese AI system can diagnose prostate cancer with accuracy comparable to human pathologists, offering potential benefits for streamlining cancer diagnosis and overcoming pathologist shortages. The system was developed using a learning algorithm and showed promise in accurately classifying malignancy levels and Gleason Grades.
A new study published in JAMA Oncology found that higher doses of radiation therapy did not improve survival rates for patients with intermediate-risk prostate cancer. However, the study did show lower rates of recurrence and tumor growth in the group receiving the higher dose, which could lead to better quality of life.
A new systematic review and meta-analysis of previous research found limited data to support the effectiveness of digital rectal exams for prostate cancer screening. The study concluded that existing studies were at risk of bias due to poor quality evidence.
A new genomic classifier score predicts aggressive prostate cancer, potentially changing treatment guidelines. The model integrates gene expression biomarker risk scores into existing risk groups, increasing accuracy and confidence in treatment recommendations.
A recent trial found that a one-off PSA test does not save lives in asymptomatic men, highlighting the need for more accurate ways to diagnose aggressive prostate cancers. The study of over 400,000 men aged 50-69 showed no significant difference in mortality rates between those who were screened and those who were not.
A single PSA test increased detection of low-risk prostate cancer, but made no significant difference in prostate cancer deaths after 10 years. This study suggests that current policy against prostate cancer screening may be justified, as potential benefits are outweighed by harms from overdetection and overtreatment.
A novel nuclear medicine imaging agent targeting copper accumulation in tumors detects prostate cancer recurrence early in patients with biochemical relapse. The new imaging agent, copper-64 chloride (64CuCl2), has a higher detection rate than fluorine-18-choline-PET/CT in patients with low levels of PSA (<1 ng/ml).
A recent study found that nearly half of all prostate cancer randomized clinical trials use lab results that disproportionately exclude black patients. The study, published in JAMA Oncology, highlights the need for researchers to adjust entry criteria to prevent racial biases.
A phase 3 clinical trial showed apalutamide treatment significantly delayed metastasis development in men with prostate cancer resistant to standard therapy. The treatment also improved survival and reduced disease progression symptoms.
A recent study revealed that patients with inherited DNA repair mutations in metastatic prostate cancer can derive similar benefits from treatment with standard therapies as other patients. Ongoing research explores the potential potency of targeted therapy with PARP inhibitors, which may offer additional therapeutic options for these ...
Researchers have developed a new method to differentiate cancerous tissue from healthy tissue in prostate cancer patients using PSMA PET/CT scans. The study found that a cutoff value of SUV max = 3.15 can accurately diagnose prostate cancer with high sensitivity and specificity.
PSMA PET/CT detects prostate cancer recurrence earlier than current imaging modalities, enabling more effective salvage radiotherapy. Nearly half of patients with biochemical recurrence show positive results, with lesions often found in bone and perirectal lymph nodes.
A large retrospective study found that obese men and those with metabolic syndrome had a higher risk of biochemical recurrence after radical prostatectomy. Patients with obesity had a 32% higher chance of recurrence compared to those with normal weight, while those with metabolic syndrome had over four-fold increased risk.
Researchers confirmed a mechanistic link between HSD17B4 and treatment-resistant prostate cancer. The study found that men lacking a specific isoform of the gene are more susceptible to aggressive prostate cancer.
A new genetic tool predicts the age of onset for aggressive prostate cancer, guiding decisions on PSA screening. The polygenic hazard score is a highly significant predictor of age at diagnosis, estimating individual genetic risk.
A new study found that a Mediterranean diet rich in fish, boiled potatoes, fruits, vegetables, legumes, and olive oil was associated with a lower risk of aggressive prostate cancer. The diet showed a protective effect on more aggressive tumors, but other dietary patterns had little to no correlation.
A new genetic risk model predicts age of onset for aggressive prostate cancer, guiding screening decisions. Men with high scores are at almost three-fold greater risk of developing aggressive disease.
Researchers at Hokkaido University have identified a cellular protein called STAP-2 that stabilizes the EGFR signaling pathway, leading to increased cell proliferation and tumor formation in prostate cancer. Suppressing STAP-2 with inhibitors could potentially treat Gefitinib-resistant prostate cancers.
A study published in Oncotarget identifies a key step in the modification of Snail1, which can alter its structure and function to promote prostate cancer cell migration. The researchers found that preventing this modification can abolish the migratory and invasive properties of human prostate cancer cells.
A five-year, nearly $12 million study will compare the effectiveness of two radiation treatments for prostate cancer, proton therapy and intensity-modulated radiation therapy (IMRT). The study aims to determine if proton therapy has fewer side effects compared to IMRT.
An international panel of experts has developed a comprehensive set of recommendations for genetic counseling and testing in men with high-risk prostate cancer. The guidelines aim to inform screening, treatment planning, and personalized care, taking into account the rapidly evolving field of practice.
A new study found that a shorter course of radiation therapy using higher doses over fewer days may provide a better outcome for men with intermediate-risk prostate cancer. The study analyzed data from over 5,000 men and showed a significant 13% reduction in the risk of recurrence with hypofractionated radiation therapy (HRT) compared ...
A study by Australian researchers demonstrates that PSMA PET scans can identify prostate cancer patients who would benefit from salvage radiation treatment. The study shows an overall treatment response of 72 percent, with men having negative or fossa-confined PSMA having the highest treatment response to SRT.
A new method using single-cell genomics can help identify potentially lethal prostate tumors before surgery, improving risk assessment and treatment decisions. The approach analyzes genomic patterns in biopsy cores, assigning a score based on clonality and genetic aberrations.
A new study at the University of Michigan identifies a pathway that links efferocytosis, the process of removing dead cells, to tumor growth in metastatic prostate cancer. The researchers found that a pro-inflammatory protein called CXCL5 accelerates tumor growth and sheds light on novel effective cancer therapies.
The Prostate Health Index test influences physician decisions to perform biopsies, with only 36% of men receiving biopsies when phi testing was included in the assessment compared to 60% before its availability. The study also found a reduction in low-grade prostate cancers detected.
Researchers detected TMPRSS2-ERG fusions in 45% of analyzed prostate cancers, with those retaining interstitial genes showing lower risk of progression. The study suggests that identifying the formation mechanism of gene fusions could help stratify patients into more well-defined risk groups.
A recent study found that dietary isoflavone intake was associated with an elevated risk of advanced prostate cancer, but not non-advanced cases. Isoflavones are a type of phytoestrogen found in soybeans and other plants.
A study published in Annals of Oncology has identified genetic markers that may predict resistance to a specific therapy used for treating advanced prostate cancer. The researchers found that understanding the genetic markers of tumors can help healthcare providers match a therapy that is likely to succeed on the first try.
A new Northwestern Medicine study shows proton therapy outperforms intensity-modulated radiation therapy (IMRT) in five-year overall survival rates, with a 93.25% rate for proton patients compared to 88.43% for IMRT patients. Proton therapy also reduces complications and secondary malignancies, particularly for younger patients.
A recent study by UNC Lineberger Comprehensive Cancer Center researchers found that more than half of men with prostate cancer prefer preserving sexual function, but this preference was not strongly linked to the choice of treatment strategy. Active surveillance is widely recognized as the best option for preserving sexual function, ye...
A new gene expression biomarker has been developed to diagnose prostate cancer type and aggressiveness, enabling clinicians to tailor treatment plans. The study found the diagnostic test to be more effective than standard clinical tests in predicting aggressive disease.
Researchers found that nerves stimulate the formation of new blood vessels that promote tumor growth in prostate cancer. They discovered an "angio-metabolic switch" triggered by norepinephrine binding to endothelial cells, which changes how cells metabolize glucose, favoring glycolysis.
Researchers discovered a testosterone-related genetic variant that can predict individual patient responses to specific prostate cancer therapies. The studies suggest that men with this variant would benefit from personalized treatment plans targeting hormonal pathways.
Androgen receptor targeted imaging is emerging as a potential modality for early, rapid, and efficient diagnosis of prostate cancer. Current medical imaging reviews discuss traditional diagnostic approaches and summarize current imaging approaches using PSMA, BN, and AR targeted imaging.
A new study found that surgical cancer centers in England are investing heavily in unproven technologies to stay competitive, despite a lack of evidence on their effectiveness. This trend has led to the closure of several centers, with patients often traveling to alternative facilities offering robotic surgery.
The University of Texas at San Antonio has received a $354,617 grant to support the development of a novel microscope for detecting prostate cancer through urine samples. This noninvasive approach aims to improve accuracy compared to current clinical practices.
A groundbreaking collaboration has been awarded $2.5 million to explore an innovative new treatment path for breast and prostate cancer. The project aims to 'reprogram' hormone receptors, potentially transforming the lives of those affected by these cancers.
The STAMPEDE trial presents late-breaking results from two new treatments for patients with high risk prostate cancer. Patients starting long-term hormone therapy may benefit equally from docetaxel and abiraterone acetate plus prednisolone, with both treatments providing a survival advantage over standard care alone.
Researchers have developed a new approach to precisely identify and localize prostate cancer tumors while protecting healthy tissue. The double targeting ligand RPS-027 binds to both PSMA and albumin, reducing kidney uptake and increasing tumor-to-tissue ratios for improved therapeutic profile.
Guidelines recommending against routine PSA-based screening may be revised due to compatible evidence showing screening reduces prostate cancer mortality. The benefits of screening outweigh potential harms of overdiagnosis and overtreatment, but how to implement screening is still a question.
Researchers found that anti-hormone therapy can activate DNA repair enzyme PARP, causing cancer cells to become more aggressive. Combining PARP inhibitors with anti-hormone therapy treatment may help reduce prostate cancer recurrence and increase survival rates.
A new imaging technique has been developed to uncover oxygen levels in prostate tumours, potentially leading to a non-invasive way to determine which tumours are more difficult to treat. The technique uses light and sound to image the strength of blood vessels in tumours, helping doctors identify patients with harder-to-treat cancers.
Researchers at The Wistar Institute have developed a gene-based delivery system that instructs the body to generate therapeutic antibodies against cancer cells. This technology has shown promising results in treating prostate cancer by binding to cancer cells and recruiting immune cells, resulting in tumor shrinkage and improved survival.
Researchers at Mayo Clinic have identified a link between SPOP gene mutations and treatment resistance in prostate cancer. The discovery suggests ways to improve therapy by using these mutations as biomarkers. This breakthrough could lead to more effective treatments for this common and deadly form of cancer.
Researchers at Johns Hopkins Medicine discovered a biochemical process that gives prostate cancer cells the ability to change shape and invade other tissues. The study found that a gene called AIM1 is deleted in approximately 20-30% of prostate cancers confined to the gland and 40% of metastatic prostate cancers.
A systematic review and meta-analysis found that both bisphosphonates and denosumab improve bone mineral density in men with nonmetastatic prostate cancer receiving androgen deprivation therapy. Further trials are needed to confirm fracture reduction outcomes.
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.